+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 88 Pages
  • January 2021
  • Region: North America
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5241402
The North America Antibiotics Market is expected to witness market growth of 4.6% CAGR during the forecast period (2020-2026).

Antibiotics are the combination of medicines that are used to cure an infection caused by germs-bacteria and some parasites, by restricting the growth of microorganisms or destroying them. These antibiotics are also called antibacterial or antimicrobials. With the discovery of the antibiotic penicillin in 1920, many antibiotic compounds have been utilized to cure various bacterial infections. Growing incidents of chronic and infectious diseases in the world and the effectiveness of antibiotics to cure a broad spectrum of bacterial infections have resulted in the swift growth of the antibiotics market.

The development of unique approaches for advanced antibiotics for curing bacterial infections and numerous clinical trials drives the global antibiotics market. Moreover, the rising rates of infectious diseases like pneumonia, tuberculosis, HIV/AIDS, and malaria will boost the market. Following this, the increasing gap in the demand and supply of antibiotics also propel the market growth. Huge investments in research and development by biotech companies are estimated to increase the global antibiotics market.

Furthermore, favorable government regulations like the Generating Antibiotics Incentives Now (GAIN) Act provide a push to research and development processes, offering various opportunities for key companies. Although, the indiscriminate and sustained utilization of antibiotics in the last few years has helped in the development of antibiotic-resistant bacteria and pathogens. There are some infections like pneumonia; gonorrhea and tuberculosis that were initially susceptible to antibiotics have become resistant to these drugs. However, the market is estimated to observe remarkable growth because of the development of advanced molecules and novel combination therapies to cure antibiotic-resistant microbial infections.

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Scope of the Study

Market Segments covered in the Report:

By Action Mechanism
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors,
  • Mycolic Acid Inhibitors

By Drug Class
  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides,
  • Others

By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled
  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antibiotics Market, by Action Mechanism
1.4.2 North America Antibiotics Market, by Drug Class
1.4.3 North America Antibiotics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players
Chapter 4. North America Antibiotics Market by Action Mechanism
4.1 North America Cell Wall Synthesis Inhibitors Market by Country
4.2 North America Protein Synthesis Inhibitors Market by Country
4.3 North America DNA Synthesis Inhibitors Market by Country
4.4 North America RNA Synthesis Inhibitors Market by Country
4.5 North America Mycolic Acid Inhibitors Market by Country
Chapter 5. North America Antibiotics Market by Drug Class
5.1 North America Cephalosporin Market by Country
5.2 North America Penicillin Market by Country
5.3 North America Fluoroquinolone Market by Country
5.4 North America Macrolides Market by Country
5.5 North America Carbapenem Market by Country
5.6 North America Aminoglycosides Market by Country
5.7 North America Sulfonamides Market by Country
5.8 North America Others Market by Country
Chapter 6. North America Antibiotics Market by Country
6.1 US Antibiotics Market
6.1.1 US Antibiotics Market by Action Mechanism
6.1.2 US Antibiotics Market by Drug Class
6.2 Canada Antibiotics Market
6.2.1 Canada Antibiotics Market by Action Mechanism
6.2.2 Canada Antibiotics Market by Drug Class
6.3 Mexico Antibiotics Market
6.3.1 Mexico Antibiotics Market by Action Mechanism
6.3.2 Mexico Antibiotics Market by Drug Class
6.4 Rest of North America Antibiotics Market
6.4.1 Rest of North America Antibiotics Market by Action Mechanism
6.4.2 Rest of North America Antibiotics Market by Drug Class
Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

Companies Mentioned

  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Methodology

Loading
LOADING...